Prevalence of large granular lymphocytosis in patients with chronic myelogenous leukemia (CML) treated with dasatinib

Posted by rob on December 30, 2010 under Uncategorized | Comments are off for this article

Dasatinib is a potent inhibitor of the BCR-ABL tyrosine kinase and is effective treatment for patients with chronic myelogenous leukemia (CML) resistant to or intolerant of treatment with imatinib. Large granular lymphocytes (LGLs) normally account for only 10–15% of circulating mononuclear cells in adults with most LGLs having an NK-cell phenotype (CD3?, CD16+, CD56+). Proliferation of LGLs has been reported in a small number of patients treated with dasatinib. Mustjoki et al demonstrated that LGL proliferation occurred in both CML and Philadelphia chromosome positive ALL patients treated with dasatinib . Both T- and NK-cell phenotypes were observed in patients with LGL lymphocytosis. In patients with T-cell phenotypes, clonality was demonstrated through T-cell receptor gene rearrange…
More